IP Library Granted Patent US 7,311,901
Granted Patent B2
US 7,311,901 · App. 10/962,204 · Granted Dec 25, 2007

Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery

Assignee: Samyang Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,311,901
App. No.
10/962,204
Granted
Dec 25, 2007
Kind
B2
Abstract

The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles in an aqueous solution, comprising the amphiphilic block copolymer and a polylactic acid derivative wherein one or more ends of the polylactic acid are covalently bound to at least one carboxyl group.

Claims (17)

1. A block copolymer comprising hydrophilic A blocks and hydrophobic B blocks with a terminal hydroxyl group, wherein said terminal hydroxyl group of the hydrophobic block is substituted with tocopherol or cholesterol, wherein the hydrophilic A block is a member selected from the group consisting of polyalkylene glycols, polyvinyl alcohols, polyvinyl pyrrolidones, and polyacryl amides wherein the hydrophobic B block is a member selected from the group consisting of polylactides, polyglycolides, polycaprolactone, polydioxan-2-one, polylactic-co-glycolide, polylactic-co-dioxan-2-one, polylactic-co-caprolactone and polyglycolic-co-caprolacton.

2. The block copolymer according to claim 1 , which is an A-B type diblock copolymer or a B-A-B type triblock copolymer.

3. The block copolymer according to claim 1 , wherein the ratio of the hydrophilic A block to the hydrophobic B block is within the range of 30:70 to 97:3 by weight.

4. The block copolymer according to claim 1 , wherein the hydrophilic A block has a number average molecular weight of 200 to 50,000 Daltons.

5. The block copolymer according to claim 1 , wherein the hydrophobic B block has a weight average molecular weight of 50 to 50,000 Daltons.

6. A block copolymer, which is represented by the following formula:

R 1′ —O—[R 3′ ] x′ —[R 4′ ] m′ —[R 5′ ] n′ —C(═O)—(CH 2 ) x′ —C(═O)—O—R 2′   (I′)

wherein R 1′ is CH 3 —, H—[R 5′ ] n′ —[R 4′ ] m′ —, or R 2′ —O—C(═O)—(CH 2 ) x′ —C(═O)—[R 5′ ] n′ —[R 4′ ] m′ —;

R 2′ is tocopherol or cholesterol;

R 3′ is —CH 2 CH 2 —O—, —CH(OH)—CH 2 —, —CH(C(═O)—NH 2 )—CH 2 —, or

R 4′ is —C(═O)—CHZ′-O—, wherein Z′ is a hydrogen atom or methyl group;

R 5′ is —C(═O)—CHY″—O—, wherein Y″ is a hydrogen atom or methyl group, —C(═O)—CH 2 CH 2 CH 2 CH 2 CH 2 —O—, or —C(═O)—CH 2 OCH 2 CH 2 —O—;

l′ is an integer from 4-1150;

m′ is an integer from 1-300;

n′ is an integer from 0-300; and

X′ is an integer from 0-4.

7. A drug carrier comprised essentially of block copolymer according to claim 1 .

Assignments (4)
CHANGE OF ADDRESS Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 058013/0696 →
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2012
From: SAMYANG CORPORATION
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 027811/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2005
From: SEO, MIN HYO; KIM, BONG OH; CHOI, IN JA; SHIM, MYUNG SEOB; LEE, SA-WON; HYUN, MYUNG-HAN; YU, JEONG-II; CHANG, DONG-HOON; YOON, HYE-JEONG; KIM, JEONG-KYUNG
To: SAMYANG CORPORATION
Reel/Frame 016564/0985 →
Priority Claims (1)
KR 10-2003-0070667 · Oct 10, 2003 · national
Continuity (2)
Provisional Application 6051436700 · Oct 24, 2003
Related Publication 20050201972A1 · Sep 15, 2005